Project Coordinator & Principal Investigator
Phase I/II clinical trial of a novel asparaginase mutant for treatment of acute lymphatic leukemia (2021–2025)
Funding: BIRAC, India
Research Projects
Overview of ongoing and completed research projects with funding agencies and roles
Ongoing Projects
- Principal Investigator (2026-2029): Epigenomics of Mycobacterium tuberculosis Infected Bone Marrow Stem Cells and Its Implications on Drug Resistance and Host Directed Therapy, Funding agency: ANRF ARG, GoI
- Principal Investigator (2026-2028): Development of rapid non-invasive saliva based TB-RAP kit for tuberculosis diagnosis, Funding agency: DISHA 2.0, DST, GoI
- Co-Investigator (2026-2028): Digital TB elimination initiative. Funding agency: Disha 2.0, DST, GoI
- Project Co-ordinator and Principal Investigator (2021-2026): Phase I/II Clinical trial of a novel asparaginase mutant for the treatment of primary and relapse acute lymphatic leukemia, Funding agency: BIRAC, India
- Principal Investigator (2025-2027): Deciphering Mycobacterial Respiratory Niches to Target Organelle Dynamics during Infection: A Translational Approach to Develop Novel Therapeutic Intervention, Funding agency: SPARC-GIANT (Indo-Germany)
- Co-Investigator (2023-2025): Smart polymeric nanoparticles based delivery system for the delivery of anti-tuberculosis drugs, Funding agency: SPARC (Indo-Russia).
Completed Projects
- CO-PI (2025-2027):
Project: Erasmus+ Mobility Grant (Indo-Germany) - Principal Investigator (2023-2025):
Project: E. coli L-asparaginase variant for the treatment of acute lymphoblastic leukemia (ALL).
Funding agency: SERB, India - Co- PI (2021):
Project: Development of disinfection systems for the prevention and spread of CoVID-19 through indoor air.
Funding agency: BIRAC, India - Principal Investigator (2021-2022):
Project: Development of Novel Benzo Fused Heterocycles to Improve the Treatment of Drug Resistant Tuberculosis.
Funding agency: DBT, India - Principal Investigator (2017-2022):
Project: To study the role of mesenchymal stem cells in the pathogenesis of tuberculosis in bone marrow.
Funding agency: DBT, India - Principal Investigator (2018-2022):
Project: Pharmacological evaluation of a novel asparaginase used for the treatment of acute lymphoblastic leukemia (ALL).
Funding agency: BRNS, India - Co-Leader, Centre of Excellence (2015-2020):
Project: Centre of Excellence on “Translational research program on gastrointestinal bacterial pathogens.
Funding agency: DBT - Principal Investigator (2020-2022):
Project: Development of theranostic targeted magnetic nanoparticles for diagnostics and treatment of tuberculosis.
Funding agency: Indo-Russia (DST-RFBR) - Principal Investigator (BIG Innovation Grant) (2016-2018):
Project: Development of novel asparaginase based therapy for the treatment of acute lymphatic leukemia.
Funding agency: BIRAC, DBT, India - Principal Investigator (2015-2018):
Project: Evaluation of antileukemic and immunogenicity properties of engineered Escherichia coli asparaginase-II for the treatment of acute lymphoblastic leukemia in preclinical model.
Funding agency: DST, India - Principal Investigator (2013-2016):
Project: Identification and testing of cationic antimicrobial peptides from human granulocytes against mycobacteria: an implication on polypeptide based therapy for the treatment of tuberculosis.
Funding agency: DBT, India - Principal Investigator (2013-2016):
Project: Delivery of Drug-encapsulating Nanoparticles to Macrophages and their Role in the Induction of Innate and Adaptive Immune Responses for the Treatment of Tuberculosis.
Funding agency: DST, India - Principal Investigator (2012-2015):
Project: Identification and elucidation of role of glycoproteins in the pathogenesis of Mycobacterium tuberculosis: a study on the implications of mycobacteria glycoproteins in the modulation of host immune responses and drug targets.
Funding agency: ICMR, India - Principal Investigator (2010-2014):
Project: Nanobead based novel strategies for the efficient delivery of drug molecules for the treatment of tuberculosis.
Funding agency: DBT, India - Principal Investigator (2010-2013):
Project: Improving the properties of L-asparaginase used for the treatment of acute lymphatic leukemia.
Funding agency: DST, India - Principal Investigator (2010):
Project: Construction of Mycobacterium tuberculosis glum mutants by site directed mutagenesis.
Funding agency: OSDD, CSIR
Research Projects
Overview of ongoing and completed research projects with funding agencies and roles
Ongoing Projects
Principal Investigator
Deciphering Mycobacterial Respiratory Niches to develop novel therapeutic interventions (2025–2027)
Funding: SPARC-GIANT (Indo-Germany)
Deciphering Mycobacterial Respiratory Niches to develop novel therapeutic interventions (2025–2027)
Funding: SPARC-GIANT (Indo-Germany)
Co-Principal Investigator
Smart polymeric nanoparticles for anti-tuberculosis drug delivery (2023–2025)
Funding: SPARC (Indo-Russia)
Smart polymeric nanoparticles for anti-tuberculosis drug delivery (2023–2025)
Funding: SPARC (Indo-Russia)
Co-Principal Investigator
Erasmus+ Mobility Grant (Indo-Germany) (2025–2027)
Erasmus+ Mobility Grant (Indo-Germany) (2025–2027)
Principal Investigator
E. coli L-asparaginase variant for treatment of acute lymphoblastic leukemia (2023–2025)
Funding: SERB, India
E. coli L-asparaginase variant for treatment of acute lymphoblastic leukemia (2023–2025)
Funding: SERB, India
Completed Projects
Co-Principal Investigator
Disinfection systems to prevent COVID-19 spread (2021)
Funding: BIRAC, India
Disinfection systems to prevent COVID-19 spread (2021)
Funding: BIRAC, India
Principal Investigator
Novel benzo-fused heterocycles for drug-resistant tuberculosis (2021–2022)
Funding: DBT, India
Novel benzo-fused heterocycles for drug-resistant tuberculosis (2021–2022)
Funding: DBT, India
Principal Investigator
Role of mesenchymal stem cells in tuberculosis pathogenesis (2017–2022)
Funding: DBT, India
Role of mesenchymal stem cells in tuberculosis pathogenesis (2017–2022)
Funding: DBT, India
Principal Investigator
Pharmacological evaluation of novel asparaginase (2018–2022)
Funding: BRNS, India
Pharmacological evaluation of novel asparaginase (2018–2022)
Funding: BRNS, India
Co-Leader, Centre of Excellence
Translational Research Program on Gastrointestinal Bacterial Pathogens (2015–2020)
Funding: DBT, India
Translational Research Program on Gastrointestinal Bacterial Pathogens (2015–2020)
Funding: DBT, India
Principal Investigator
Magnetic nanoparticles for tuberculosis diagnostics & treatment (2020–2022)
Funding: Indo-Russia (DST–RFBR)
Magnetic nanoparticles for tuberculosis diagnostics & treatment (2020–2022)
Funding: Indo-Russia (DST–RFBR)
Principal Investigator (BIG Grant)
Asparaginase-based therapy for leukemia (2016–2018)
Funding: BIRAC, DBT, India
Asparaginase-based therapy for leukemia (2016–2018)
Funding: BIRAC, DBT, India
Principal Investigator
Engineered E. coli asparaginase-II for leukemia (2015–2018)
Funding: DST, India
Engineered E. coli asparaginase-II for leukemia (2015–2018)
Funding: DST, India
Principal Investigator
Antimicrobial peptides against mycobacteria (2013–2016)
Funding: DBT, India
Antimicrobial peptides against mycobacteria (2013–2016)
Funding: DBT, India
Principal Investigator
Drug-encapsulating nanoparticles for tuberculosis (2013–2016)
Funding: DST, India
Drug-encapsulating nanoparticles for tuberculosis (2013–2016)
Funding: DST, India
Principal Investigator
Glycoproteins in tuberculosis pathogenesis (2012–2015)
Funding: ICMR, India
Glycoproteins in tuberculosis pathogenesis (2012–2015)
Funding: ICMR, India
Principal Investigator
Nanobead-based drug delivery strategies (2010–2014)
Funding: DBT, India
Nanobead-based drug delivery strategies (2010–2014)
Funding: DBT, India
Principal Investigator
Improving L-asparaginase properties (2010–2013)
Funding: DST, India
Improving L-asparaginase properties (2010–2013)
Funding: DST, India
Principal Investigator
Mycobacterium tuberculosis glum mutants study (2010)
Funding: OSDD, CSIR
Mycobacterium tuberculosis glum mutants study (2010)
Funding: OSDD, CSIR
MFS-Department of Biosciences and Biomedical Engineering,
Explore
- © Copyright 2025